Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note FDA-cleared MRD assay; only FDA-cleared MRD assay for multiple myeloma. Used in 180+ active biopharma trials. Company announced June 2026 intent to pursue separation of MRD and Immune Medicine businesses.
TCR-depleting antibody program
Preclinical · ActiveModality: antibody
Target TCR (T-cell receptor)
Indications
ankylosing spondylitis(Preclinical)
Status note Per 10-K business section, company completed a preclinical data package for the TCR-depleting antibody program in ankylosing spondylitis.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
H. Lee Moffitt Cancer Center and Research Institute
—
Multiple Myeloma
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.